Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Leteprinim. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 16/20 | 0.48 |
| ▸ | PNP | P00491 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leteprinim SCHEMBL6935182 | 0.88 | HPRT1 (0.49) | HPRT1PNPLMNA | |
| Leteprinim SCHEMBL6931317 | 0.88 | HPRT1 (0.49) | HPRT1PNP | |
| Leteprinim SCHEMBL194355 | 0.88 | HPRT1 (0.49) | HPRT1PNPLMNA | |
| SCHEMBL1247298 | 0.84 | GAA (0.54) | HPRT1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7438455 | 0.80 | HDAC3 (0.52) | HPRT1LMNAKMT2A | |
| SCHEMBL7397072 | 0.77 | HPRT1 (0.59) | HPRT1PNP | |
| SCHEMBL7399609 | 0.74 | HPRT1 (0.56) | HPRT1PNP | |
| SCHEMBL7374581 | 0.74 | HPRT1 (0.64) | HPRT1PNP | |
| SCHEMBL5258348 | 0.74 | TK1 (0.54) | HPRT1PNP | |
| SCHEMBL7399531 | 0.73 | HPRT1 (0.55) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106947-A1 | COMPOSITIONS AND METHODS FOR INDUCED STEM CELL DIFFERENTIATION TO NEURONAL LINEAGE | EXIR, INC. (US) | 2025-05-22 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240207325-A1 | Pancreatic Islets as Protein Factories | BIOCRINE AB (SE) | 2024-06-27 | — | — | US | claimed |
| EP-4323393-A1 | PANCREATIC ISLET ORGANOIDS AS PROTEIN FACTORIES | BioCrine AB (SE) | 2024-02-21 | — | — | EP | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022218876-A1 | PANCREATIC ISLET ORGANOIDS AS PROTEIN FACTORIES | BIOCRINE AB (SE) | 2022-10-20 | — | — | WO | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-10251778-B2 | Therapeutics dispensing device and methods of making same | BAYLOR COLLEGE OF MEDICINE (US) | 2019-04-09 | — | — | US | claimed |
| US-20150190279-A1 | THERAPEUTICS DISPENSING DEVICE AND METHODS OF MAKING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2015-07-09 | — | — | US | claimed |
| EP-2879761-A1 | THERAPEUTICS DISPENSING DEVICE AND METHODS OF MAKING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2015-06-10 | — | — | EP | claimed |
| CN-1549718-A | Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries | 爱尔康公司 | 2004-11-24 | — | — | CN | claimed |
| EP-1420791-A4 | USE OF COMPOUNDS FOR TREATING CONDITIONS RESULTING FROM INJURY TO THE CORNEAL NERVE AFTER LASIK AND OTHER OCULAR SURGERIES OR TRAUMA | ALCON INC (CH) | 2004-09-15 | — | — | EP | claimed |
| US-20040162315-A1 | Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma | ALCON, INC. (CH) | 2004-08-19 | — | — | US | claimed |
| WO-2004058258-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-07-15 | — | — | WO | claimed |
| EP-1420791-A1 | USE OF COMPOUNDS FOR TREATING CONDITIONS RESULTING FROM INJURY TO THE CORNEAL NERVE AFTER LASIK AND OTHER OCULAR SURGERIES OR TRAUMA | Alcon, Inc. (CH) | 2004-05-26 | — | — | EP | claimed |
| US-20040049134-A1 | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain | TOSAYA CAROL A (US) | 2004-03-11 | — | — | US | claimed |
| WO-2003020281-A1 | USE OF COMPOUNDS FOR TREATING CONDITIONS RESULTING FROM INJURY TO THE CORNEAL NERVE AFTER LASIK AND OTHER OCULAR SURGERIES OR TRAUMA | ALCON, INC. (CH) | 2003-03-13 | — | — | WO | claimed |
| CN-1325308-A | Use of neurotrophic factor stimulators for treatment of ophthalmic neurodegenerative diseases | ALCON LAB INC (US) | 2001-12-05 | — | — | CN | claimed |
| EP-1135134-A1 | USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF OPHTHALMIC NEURODEGENERATIVE DISEASES | Alcon Laboratories, Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032197-A1 | USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF OPHTHALMIC NEURODEGENERATIVE DISEASES | ALCON LABORATORIES, INC. (US) | 2000-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HPRT1 1619/4885PNP 1179/4885MEN1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.